Reasonable design of antibody mimetics for targeting glioma and small cell lung cancer

European Journal of Cancer Prevention

Volumn 18, Issue 6, 2009, Pages 431-435

  Jiang, Tao ^a   Zhang, Liang ^a   Wang, Jian ^a   Li, Xiaofei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antibody mimetics; Glioma; Immunotoxin; Small cell lung cancer

Indexed keywords

AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BT32 A6; MONOCLONAL ANTIBODY TB2A36C3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL STRAIN; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; RAJI CELL;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BIOMIMETICS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; DIPHTHERIA TOXIN; DRUG DESIGN; EPITOPES; GLIOMA; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; PROGNOSIS; RECOMBINANT FUSION PROTEINS; SMALL CELL LUNG CARCINOMA;

EID: 70349789686     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32832e0912     Document Type: Article

References (11)

1. Adams GP, Weiner LM (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147-1155.
2. Better M, Chang CP, Robinson RR, Horwitz AH (1998). Escherichia coli secretion of an active chimeric antibody fragment. Science 240:1041-1043.
3. Borg NA, Ely LK, Beddoe T, Macdonald WA, Reid HH, Clements CS, et al. (2005). The CDR3 regions of an immunodominant T cell receptor dictate the energetic landscape of peptide-MHC recognition. Nat Immunol 6:171-180.
4. Fujimori K, Fisher DR,Weinstein JN (1991). Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. Cancer Res 51:4776-4784.
5. Holliger P, Hudson PJ (2005). Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136.
6. Holliger P, Prospero T,Winter G (1993). Diabodies: small bivalent and bispecific antibody fragment. PNAS 90:6444-6448.
7. Jirholt P, Strandberg L, Jansson B, Krambovitis E, Sö derlind E, Borrebaeck CA, et al. (2001). A central core structure in an antibody variable domain determines antigen specificity. Protein Eng 14:67-74.
8. Kohler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
9. Qin WS, Feng JN, Li Y, Lin Z, Shen B (2006). Fusion protein of CDR mimetic peptide with Fc inhibit TNF-a induced cytotoxicity. Mol Immunol 43:660-666.
10. Ward ES, Gussow D, Griffiths AD, Jones PT,Winter G (1989). Binding activities of a repertoire of single immunoglobulin variable domain secreted from Escherichia coli. Nature 341:544-546. (Pubitemid 19252529)
11. Xu JL, Davis MM (2000). Diversity in the CDR3 region of VH is sufficient for most antibody specificities. Immunity 13:37-45.